Infection with Chlamydia pneumoniae in Brooklyn

Chirgwin, Keith; Roblin, Patricia M.; Gelling, Maureen; Hammerschlag, Margaret R.; Schachter, Julius

doi:10.1093/infdis/163.4.757

Cited by 126 publications

(62 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, not all C. pneumoniae infections provoke a humoral immune response detectable by microimmunofluorescence [29], and some isolation studies from subjects with airway dysfunction have found rates higher than expected on the basis of serological data [13]. This suggests that the subjects in this study have a higher prevalence than normal children, that serological studies have underestimated the true prevalence of this organism, or both.…”

Section: Discussionmentioning

confidence: 55%

Chronic Chlamydia pneumoniae infection and asthma exacerbations in children

Cunningham¹,

Johnston²,

Julious³

et al. 1998

Eur Respir J

208

127

View full text Add to dashboard Cite

This study was undertaken to investigate the reported association between Chlamydia pneumoniae and Mycoplasma pneumoniae infection and the expression of asthma-related symptoms. One hundred and eight children with asthma symptoms, aged 9-11 yrs, completed a 13 month longitudinal study. The children maintained a daily diary of respiratory symptoms and peak flow rates. When respiratory symptoms were reported an investigator was called and a nasal aspirate obtained. In total 292 episodes were reported. After the study 65 children provided samples when asymptomatic. The presence of infection was investigated by the polymerase chain reaction for C. pneumoniae and M. pneumoniae and C. pneumoniae secretory immunoglobulin A (IgA) was detected by amplified enzyme immunoassay. C. pneumoniae detections were similar between the symptomatic and asymptomatic episodes (23 versus 28%, respectively). Children who reported multiple episodes also tended to remain PCR positive for C. pneumoniae suggesting chronic infection (p< 0.02). C. pneumoniae-specific secretory-IgA antibodies were more than seven times greater in subjects who reported four or more exacerbations in the study compared to those who reported just one (p<0.02). M. pneumoniae was found in two of 292 reports and in two of 65 asymptomatic samples. In conclusion, chronic Chlamydia pneumoniae infection is common in schoolage children and immune responses to C. pneumoniae are positively associated with frequency of asthma exacerbations. We suggest that the immune response to chronic C. pneumoniae infection may interact with allergic inflammation to increase asthma symptoms. In contrast Mycoplasma pneumoniae was not found to be important in this study.

show abstract

Section: Discussionmentioning

confidence: 55%

Chronic Chlamydia pneumoniae infection and asthma exacerbations in children

Cunningham¹,

Johnston²,

Julious³

et al. 1998

Eur Respir J

208

127

View full text Add to dashboard Cite

show abstract

“…pneumoniae CAP [29,30] although one study described C. pneumoniae infection during all seasons with higher incidence in summer months [31]. C. pneumoniae epidemics are characterised by an initial high incidence period which lasts a few months to two-three years followed by three-four years of lower incidence [32].…”

Section: Discussionmentioning

confidence: 99%

Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles

et al. 2005

View full text Add to dashboard Cite

Short running head: C. pneumoniae and M. pneumoniae pneumonia 2 SUMMARYThe purpose of our retrospective three-year-study was to analyse and compare clinical and epidemiological characteristics in hospitalized patients older than six years with communityacquired pneumonia (CAP) caused by Chlamydia pneumoniae (87 patients) and Mycoplasma pneumoniae (147 patients). C. pneumoniae and M. pneumoniae infection was confirmed by serology. C. pneumoniae patients were older (42.12 year vs. 24.64 year), and were less likely to have a cough, rhinitis, and hoarseness (p<0.001). C. pneumoniae patients had higher levels of C-reactive protein (CRP), and aspartate aminotransferase (AST) than M. pneumoniae patients (p<0.001). Pleural effusion was recorded more frequently in patients with M. pneumoniae (8.84% vs.3.37%). There were no characteristic epidemiological and clinical findings that would distinguish CAP caused by M. pneumoniae from C. pneumoniae.However, some factors are indicative for C. pneumoniae such as older age, lack of cough, rhinitis, hoarseness, and higher value of CRP, and AST.

show abstract

“…We predicted (from our previous research and that of other published studies) that the prevalence of IgG anti-C. pneumoniae antibodies at titers of Ն64 would be approximately 15% to 20% in the population under study. 3,15,16 With the nominal ␣ or type I error level (two-tailed) set at .05, and the ␤ or type II error level set at .20 (giving a power of 80%), and after we applied the z statistic for dichotomous variables, we estimated that 72 to 162 patients would be required in each of the matched groups to detect a difference of 15% to 20% in the frequencies of such titers. 17 A conditional logistic regression method for matched data, implemented in the EGRET statistical package, 18 was used to explore possible associations of C. pneumoniae antibody levels and the matched variables with hypertension.…”

Section: Analysis Of Datamentioning

confidence: 99%

Chlamydia pneumoniae Antibodies in Severe Essential Hypertension

Cook

Lip²,

Davies³

et al. 1998

Hypertension

View full text Add to dashboard Cite

Abstract-Several studies have implied an association between Chlamydia pneumoniae (C. pneumoniae) and cardiovascular disease. Our study was designed to determine whether this organism is associated with severe essential hypertension in a multiracial British population. Antibodies to C. pneumoniae were measured by microimmunofluorescence in 123 patients with chronic severe hypertension and 123 control subjects, matched for ethnic origin, age, sex, and smoking habit, admitted to the same hospital with various noncardiovascular, nonpulmonary disorders. Previous infection was defined by IgG 64 to 256, provided that there was no detectable IgM. Multiple regression analyses of matched and unmatched data were used to investigate the influences of antibody levels and potential confounding factors (ethnic origin, age, sex, smoking habit, diabetes mellitus, and social deprivation) on hypertension. A portion of the hypertensive patients underwent echocardiography, estimation of left ventricular mass index, and measurements of fibrinogen, D-dimer, and von Willebrand factor concentrations. Thirty-five percent of hypertensive patients and 17.9% of matched control subjects had antibody titers consistent with previous C. pneumoniae infection. The hypertensive patients differed significantly from their matched control subjects in their level of previous infection, with an odds ratio of 2.5 (95% confidence interval, 1.3 to 4.7). There were no significant differences in antibody levels between patients with left ventricular hypertrophy and those without it. Fibrinogen, D-dimer, and von Willebrand factor concentrations were not significantly associated with antibody levels. These data support an association of C. pneumoniae with severe essential hypertension. They provide no evidence of a predisposition to develop left ventricular hypertrophy in hypertensive patients with C. pneumoniae infection or of associations with hypercoagulability or endothelial dysfunction. (Hypertension. 1998;31:589-594.)

show abstract

Infection with Chlamydia pneumoniae in Brooklyn

Cited by 126 publications

References 14 publications

Chronic Chlamydia pneumoniae infection and asthma exacerbations in children

Chronic Chlamydia pneumoniae infection and asthma exacerbations in children

Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles

Chlamydia pneumoniae Antibodies in Severe Essential Hypertension

Contact Info

Product

Resources

About